financials have been released, page-31

Whether its a SPP or a placement, that fact remains that POH still does not have a plan to fund Oxy through to commercialization and the March announcement of funding will not remove that uncertainty.

Perhaps one of those milestone payments Esra was talking about on you-tube is successful completion of phase II for oxycodone?

What I do find interesting is that they have flagged a capital raising to the market before negotiations are completed. To me that seems a bit silly if they were to raise funds based on the VWAP of the shareprice over a certain period. So to me this discounts a vanilla raising via brokers. Convertible note is a possibility, or perhaps a cornerstone investor?

What is does mean though is that there is probably no upfront for the anti-cellulite product.